Skip to main content
. 2019 May 10;43:211–224. doi: 10.1016/j.ebiom.2019.04.061

Fig. 5.

Fig. 5

T-DM1 treatment induced ROR1+ cells are enriched for CD44, ALDH and YAP1 target genes: (a-b) Freshly dissociated treatment naïve and treatment resistant HER2+ BC patients tumor cells were FACS sorted and analyzed for ROR1 subpopulation stained with ALDH and CD44 antibodies (Results are median +/− interquartile range (IQR) n = 5; unpaired two-sided t-test). (c-d. Patients tumor cells were either treated with vehicle (DMSO) and/or T-DM1 for 5 days, and sorted as (a) Analysis of ALDH and CD44 expression by FACS and immunofluorescence staining in ROR1+ and ROR1− subpopulation (Scale bar: 50 μM). (e) HCC1954 cells treated, maintained, sorted and analyzed as (d). (g) Cells were treated and sorted as (d), extracted total RNA followed by qRT-PCR for YAP1, TEAD1, CTGF and CCND1 in ROR1+ and ROR1− populations (Bar graph represents the mean +/− SE, n = 3; run in triplicate; p = .001, 0.01, 0.05, 0.001 and 0.001). (h) Detection of CTGF from treatment naïve and treatment exposed patients' blood serum by ELISA assay (Bar graph represents the mean +/− SE, n = 3; run in triplicate; **p < .01; Students t-test).